The preliminary results of treatment ofadvanced and recurrent malignant lymphoma by beac regimen supported with autologous hematopoietic stem cells transplantation
- 10 Downloads
Objective: High dose chemotherapy supported by autologous hematopoietic stem cells transplantation (AHSCT) has developed dramaticly in recent years and become the most effective approach to improve radical treatment for the chemo-sensitive lymphoma. The purposes of this study was to evaluate the efficacy and tolerance of preparative regimen BEAC and hematopoietic reconstitution after high dose chemotherapy in Chinese patients with advanced and recurrent lymphoma. Methods: After confirmed complete or partial remission from conventional chemotherapy, 24 patients with advanced or recurrent lymphoma including 1 recurrent HD and 23 NHL, 16 male and 8 female with median age of 29 (13–50) years, were enrolled into this study and treated by BEAC regimen (CTX 3600–4000 mg/m2, VP-16 1200 mg/m2. BCNU 300 mg/m2 and Ara-C 1500–2000 mg/m2). 3 patients were supported by ABMT and 21 by APBSCT. Mobilization regimen for APBSCT was CTX 3500 mg/m2 + G-CSF 3.5–5 µg/kg + Dexamethasone 10 mg. Autologous hematopoietic stem cells was re-infused 24–48 h after completion of high dose chemotherapy. Results: MNC 1.3 (1.0–1.7)×108/kg and MNC 1.8 (1.0–4.4)×108, CFU-GM 5.1 (1.9–9.6)×105/kg plus CD34 + cells 2.9 (1.9–8.7)×106/kg were re-infused in the ABMT group and APBSCT group respectively. All patients obtained prompt and sustained hematopoietic reconstitution. ANC≥0.5×109/L and Pt≥2.0×109/L were at day 9 (6–17) and day 10 (0–31) respectively. 16 patients were alive with median 21 (2–69) months follow-up till end of May, 2001. 1, 2 and 3 years survival rate were 60.5%, 50.1% and 50.1%, respectively. Non-hematologic toxicity was mild and tolerable. Conclusions: High dose chemotherapy supported by AHSCT in the treatment of previously-untreated poor-prognostic and recurrent lymphoma was a safe and effective modality. Further investigation was warranted.
Key wordsLymphoma Autologous hematopoietic Stem cells Transplantation High dose chemotherapy
Unable to display preview. Download preview PDF.
- Martelli M, Vignetti M, Zinzani PL, et al. High dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplantin, and cytarabine in aggressive non- Hodgkin’s lymphoma with partial response to front line chemotherapy: A prospective randomized Italian multicenter study [J]. J Clin Oncol 1996; 14:534.PubMedGoogle Scholar
- A predictive model for aggressive non- Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project [J]. N Engl J Med 1993; 329:987.Google Scholar
- Brian JB, Matt K, Steven A, et al. Autologous hematopoietic cell transplantation for non-Hodgkin’s Lymphoma: 100 month follow-up [J]. Proc Am Soc Clin Oncol 2001; 20(part 1):9a.Google Scholar
- Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymhpomas: a phase I/II study [J]. Bone Marrow Transplantation 1997; 20:953.PubMedCrossRefGoogle Scholar
- Philip T, Guglielmi C, Chauvin F, et al. Autologous bone marrow transplantation (ABMT) versus conventional chemotherapy (DHAP) in relapsed non-Hodgins lymphoma: final analysis of the Parma randomized study (216 patient) [J]. Proc Am Soc Clin Oncol 1995; 14:340.Google Scholar